Every Form 4 that Tenax Therapeutics, Inc. (TENX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TENX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TENX filings page.
TENAX THERAPEUTICS, INC. (TENX) had a significant shareholder associated with ADAR1 Capital Management, LLC report an open-market purchase of common stock. On September 3, 2026, private investment funds managed by ADAR1 bought 900,000 shares of Tenax common stock at a weighted average price of $1.7824 per share, in multiple trades between $1.78 and $1.80. Following this transaction, entities managed by ADAR1 reported 6,524,151 shares of Tenax common stock held indirectly, with each reporting person disclaiming beneficial ownership beyond any pecuniary interest.
For TENAX THERAPEUTICS, INC. (TENX), private investment funds managed by ADAR1 Capital Management, LLC, which may be deemed ten percent owners along with Daniel Schneeberger, reported open‑market purchases of a total of 770,333 shares of common stock over August 31 to September 2, 2026. The purchases were made indirectly through these funds at weighted average prices around $1.79 per share, with individual trades ranging from $1.77 to $1.80 per share as disclosed. The reporting persons state that the securities are owned directly by the ADAR1-managed funds and that each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest, and no Rule 10b5‑1 trading plan is reported.
TENAX THERAPEUTICS, INC. (TENX) reported insider activity by ADAR1 Capital Management, LLC and Daniel Schneeberger, each a ten percent owner. Private investment funds managed by ADAR1 purchased a total of 1,025,867 shares of TENX common stock indirectly on August 20, 21 and 24, 2026 at weighted average prices around $1.75–$1.78 per share in multiple open-market transactions. The securities are held by the ADAR1-managed funds and may be deemed indirectly beneficially owned by ADAR1 and Schneeberger, who each disclaim beneficial ownership beyond any pecuniary interest.
Tenax Therapeutics, Inc. CEO Christopher Thomas Giordano exercised stock options on July 13, 2026 to acquire 8,719 common shares, including 8,500 shares at $5.94 per share and 219 shares at $3.549 per share. The aggregate exercise price for these options was paid in cash.
After the exercises, he directly owned 11,324 and 2,824 common shares in the reported accounts and continued to hold stock options covering 1,400,000 shares at a $5.89 exercise price and 450,000 shares at a $13.30 exercise price, with vesting schedules extending over several years and expirations in 2035 and 2036.
Tenax Therapeutics reported a Form 4 showing its Chief Financial Officer, Thomas R. Staab II, receiving new equity compensation. He was granted 10,000 shares of common stock as a restricted stock award and 450,000 stock options with an exercise price of $11.95 per share.
The restricted stock vests 25% ten days after the grant date of May 11, 2026, with the remaining 75% vesting in three equal installments on the four-month, eight-month and twelve-month anniversaries, contingent on continued employment. The options expire on May 11, 2036 and vest 25% on May 11, 2027, with the balance vesting in substantially equal monthly installments over the following 36 months, also subject to continued employment.
Tenax Therapeutics, Inc.’s interim CFO, Thomas McGauley, reported a stock option covering 50,000 shares of common stock at an exercise price of $12.51 per share. The option is listed as exercisable until January 30, 2029.
According to the footnote, the option vests with 50% on January 30, 2026 and 50% on May 31, 2026, subject to McGauley’s continuous service with the company. After the reported transactions, he holds 2,000 common shares directly, 1,000 shares indirectly through a child, and 5,000 shares indirectly through a spouse.
Tenax Therapeutics director Michael H. Davidson reported a new equity award and his current holdings in company securities. On 01/09/2026, he was granted a stock option to buy 30,000 shares of Tenax Therapeutics common stock at an exercise price of $13.3 per share, expiring on 01/09/2036. Following this grant, he holds 2,881 shares of common stock directly.
He also reports several existing derivative positions, including stock options covering 100,000 shares exercisable from 12/10/2025 to 12/10/2034, and options for 80,000 shares exercisable from 07/01/2026 to 07/01/2035, plus smaller option positions. In addition, he holds a pre-funded warrant for 47,500 shares with a $0.01 exercise price and no expiration date, and a warrant for 25,000 shares with a $4.5 exercise price that can terminate based on Phase 3 LEVEL Study topline data timing or on August 8, 2029.
Tenax Therapeutics CEO Christopher Thomas Giordano received a grant of 450,000 stock options on January 9, 2026. The options give him the right to buy common stock at an exercise price of $13.3 per share.
According to the vesting terms, 25% of the underlying shares vest and become exercisable on January 9, 2027, and the remaining shares vest in equal monthly installments over the following 36 months, subject to his continued employment. After this grant, he directly holds 2,605 shares of common stock and several other stock option awards with various expiration dates extending through 2035.
Tenax Therapeutics, Inc. reported a new equity award to its chief medical officer and director, Stuart Rich. On January 9, 2026, he received a grant of stock options to buy 250,000 shares of common stock at an exercise price of $13.3 per share. These options vest over time, with 25% becoming exercisable on January 9, 2027 and the remaining shares vesting in equal monthly installments over the following 36 months, conditioned on his continued employment.
After this grant, he holds 5,266 shares of common stock directly, plus additional shares held indirectly through several family trusts. The filing states that he has voting or trustee roles with these trusts but disclaims beneficial ownership of their shares except to the extent of any pecuniary interest.
Tenax Therapeutics director Gerald T. Proehl reported an equity award and updated holdings. On January 9, 2026, he received a stock option to buy 30,000 shares of common stock, representing 3,000 derivative securities acquired, with an exercise price of $13.30 per share and an expiration date of January 9, 2036.
After this grant, he directly holds 1,667 shares of common stock, stock options covering 30,000, 100,000 and 80,000 shares under various prior grants, and a pre-funded warrant for 31,654 shares with a $0.01 exercise price and no expiration date. He also holds a warrant for 16,660 shares at a $4.50 exercise price that will expire based on the timing of topline data from Tenax’s Phase 3 LEVEL Study or, at the latest, on August 8, 2029.
Tenax Therapeutics director June Sherie Almenoff reported a new stock option grant and her current equity holdings in a Form 4 filing. On January 9, 2026, she was granted a stock option for 30,000 shares of common stock at an exercise price of $13.30 per share. This option becomes exercisable on January 9, 2027 and expires on January 9, 2036, and was reported as held directly.
The filing also lists previously awarded stock options held directly, covering 100,000 shares (exercisable from December 10, 2025 to December 10, 2034), 80,000 shares (exercisable from July 1, 2026 to July 1, 2035), and two very small option positions of 4 shares each. In addition, 1,993 shares of common stock are reported as held indirectly through Meadowlark Management, LLC, with a statement that Almenoff disclaims beneficial ownership except to the extent of her pecuniary interest.
Tenax Therapeutics director Declan Doogan reported a new stock option grant. The Form 4 shows that on 01/09/2026 he received a stock option to buy 30,000 shares of Tenax common stock at an exercise price of $13.3 per share. The option is shown as exercisable on 01/09/2027 and expiring on 01/09/2036, and is held directly.
In addition to this grant, the filing lists previously awarded stock options covering 100,000 shares exercisable from 12/10/2025 and 80,000 shares exercisable from 07/01/2026, along with two very small option positions of 4 shares each. Doogan also directly holds 2,274 shares of Tenax common stock following the reported transactions.
Tenax Therapeutics director Robyn Hunter reported a new stock option grant in a Form 4 filing. On January 9, 2026, Hunter received stock options to buy 30,000 shares of common stock at an exercise price of $13.30 per share, with no cash paid for the option itself.
The options become exercisable on January 9, 2027 and expire on January 9, 2036. After this grant, Hunter directly holds 30,000 of these newly reported derivative securities, alongside other previously granted stock options in Tenax Therapeutics.
Tenax Therapeutics, Inc. director and Chief Medical Officer reported recent open-market purchases of the company’s common stock and detailed his equity holdings. On December 2, 2025, he bought 1,000 shares at a weighted average price of $9.0059, followed by 1,500 shares at $9.0786 on December 3 and 2,500 shares at $9.1992 on December 4.
After these transactions he directly owns 2,766 common shares and has additional indirect holdings of 2,500, 1,194, and 1,194 shares through specified family trusts, for which he disclaims beneficial ownership beyond his pecuniary interest. He also beneficially owns stock options over 157, 63, 119, 500,000, and 625,000 shares at stated exercise prices, with vesting tied to time-based schedules and milestones such as a Phase 3 clinical trial, FDA-related steps, and continued employment.
Tenax Therapeutics, Inc. (TENX) reported insider activity by its CEO and director, who bought common stock on three consecutive days. On 11/18/2025, the insider purchased 1,612 shares at a weighted average price of $7.7546, followed by 455 shares at $7.5091 on 11/19/2025 and 538 shares at $7.5887 on 11/20/2025. After these open‑market purchases, the insider beneficially owned 2,605 shares of Tenax common stock directly.
The filing also lists existing stock options held by the insider. These include options exercisable for 157 shares of common stock expiring on 07/06/2031, 125 shares expiring on 06/09/2032, and 437 shares expiring on 05/17/2034, along with larger grants for 1,250,000 shares at an exercise price of $5.94 expiring on 12/10/2034 and 1,400,000 shares at $5.89 expiring on 05/16/2035. The vesting of these options is tied to continued employment and follows specified annual or monthly schedules.
Tenax Therapeutics, Inc. (TENX) director reported open-market purchases of common stock and corrected how those shares are reported. On 11/17/2025, an indirect account bought 93 shares at $7.15 per share, and on 11/18/2025 it bought 1,900 shares at a weighted average price of $7.5157, for a total of 1,993 shares held through Meadowlark Management, LLC. This amended Form 4 changes the ownership form for those 1,993 shares from direct to indirect, clarifying that the director disclaims beneficial ownership beyond her economic interest.
Tenax Therapeutics (TENX) reported an insider stock purchase by its Interim CFO. On 11/17/2025, the officer bought 2,000 shares of common stock directly and now holds 2,000 shares in their own name. On the same date, they reported additional purchases of 1,000 shares held indirectly through a child and 5,000 shares held indirectly through a spouse.
The direct shares were acquired at a weighted average price of $7.337, with trades executed between $7.14 and $7.43. The spouse’s shares were bought at a weighted average price of $7.228, with trades between $7.17 and $7.30, and the child’s shares at $7.35. All transactions were coded as open-market purchases.
Tenax Therapeutics, Inc. (TENX) director reports open‑market share purchases. A company director filed a Form 4 disclosing two common stock purchases on 11/17/2025 and 11/18/2025. The director bought 93 shares at $7.15 per share and another 1,900 shares at a weighted average price of $7.5157, for a total of 1,993 common shares held directly after these trades. The filing also lists stock options giving the right to buy Tenax common stock, including 100,000 options at an exercise price of $5.94 exercisable from 12/10/2025 to 12/10/2034, and 80,000 options at an exercise price of $5.75 exercisable from 07/01/2026 to 07/01/2035, along with two smaller legacy option grants of 4 shares each.